To date, more than 100 clinical trials with human pluripotent stem cell (hPSC)-derived products have been initiated worldwide and an increasing number of potential hPSC-derived clinical products have entered early developmental pipelines. For off-the-shelf (allogeneic) products, the identification and selection of the right hPSC line early on during this process is of utmost importance as failure to do so may delay or completely stall product development. While developers acknowledge the importance of this issue, a comprehensive, accessible listing of globally available hPSC lines to inform cell line selection for clinical use has been elusive until now.  

An estimated 5-15% of people have problems with dry eyes, with symptoms including eye redness, stinging, or burning sensation, and eye fatigue. Dry eye disease (DED) occurs when the eyes’ tear glands produce insufficient or poor-quality tears which can be due to allergy or autoimmune disease, hormonal changes, aging, etc. When left untreated, DED can increase the risk of eye infections and abrasion damage to the ocular surface, which may impair vision.